File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Serious adverse drug events during deferiprone therapy in paediatric thalassaemia Patients

TitleSerious adverse drug events during deferiprone therapy in paediatric thalassaemia Patients
Authors
Keywordsdeferiprone
thalassaemia
adverse drug event
children
Issue Date2013
PublisherThe Pharmaceutical Society of Hong Kong. The Journal's web site is located at http://www.pshk.hk/main.php?id=62
Citation
The 8th Asian Conference on Pharmacoepidemiology (ACPE 2013), Hong Kong, China, 25-27 October 2013. In Hong Kong Pharmaceutical Journal, 2013, v. 20 n. 3, p. 143 How to Cite?
AbstractAim/Objective: Iron-chelation therapy is essential for transfusion-dependent thalassaemia patients. Children are particularly affected by this disease and require early chelation therapy to avoid the long term effects of iron overload. Knowledge on the incidence and nature of serious adverse drug events (e.g. neutropenia, agranulocytosis) that may lead to treatment termination is of importance in this lifelong therapy. Methods: The Hong Kong Clinical Data Analysis and Reporting System (CDARS) comprising data of more than 7 million patients was used to extract all thalassaemia patients who were receiving deferiprone below the age of 18 years. Adverse drug events (ADE) were identifi ed using a selected list of ICD-9 codes and laboratory data. All identifi ed events were assessed for causality by reviewing concomitant medications, diagnoses and laboratory data. Results: 93 patients were eligible for analysis; median age was 14 years (IQR 12-16). Median duration of deferiprone therapy was 18 months (IQR 7-32). 17 patients received monotherapy and 76 combination therapy with deferoxamine. Overall incidence rates for neutropenia, agranulocytosis, elevated liver enzymes and arthropathies were 9.7%, 5.4%, 8.6% and 3.2%; in patients with monotherapy 5.9%, 0%, 17.6% and 5.9% and with combination therapy 10.5%, 7.9%, 6.6% and 2.6%, respectively. 10 patients stopped deferiprone therapy during observation; 5, 3 and 2 patients due to agranulocytosis, arthropathies and elevated liver enzymes, respectively. 48.3% of these ADEs occurred during the fi rst 3 months of therapy. Conclusion: Combination therapy seems to be more prone for serious ADEs than monotherapy. This association must be further investigated in larger cohorts and clinical settings in paediatric patients.
DescriptionConference Theme: Applying pharmacoepidemiology to improve health care in Asia
Oral Presentation - Paediatrics – Mental and General Health
Persistent Identifierhttp://hdl.handle.net/10722/204457
ISSN

 

DC FieldValueLanguage
dc.contributor.authorBotzenhardt, Sen_US
dc.contributor.authorSing, CWen_US
dc.contributor.authorWong, ICKen_US
dc.contributor.authorNeubert, Aen_US
dc.date.accessioned2014-09-19T23:52:22Z-
dc.date.available2014-09-19T23:52:22Z-
dc.date.issued2013en_US
dc.identifier.citationThe 8th Asian Conference on Pharmacoepidemiology (ACPE 2013), Hong Kong, China, 25-27 October 2013. In Hong Kong Pharmaceutical Journal, 2013, v. 20 n. 3, p. 143en_US
dc.identifier.issn1727-2874-
dc.identifier.urihttp://hdl.handle.net/10722/204457-
dc.descriptionConference Theme: Applying pharmacoepidemiology to improve health care in Asia-
dc.descriptionOral Presentation - Paediatrics – Mental and General Health-
dc.description.abstractAim/Objective: Iron-chelation therapy is essential for transfusion-dependent thalassaemia patients. Children are particularly affected by this disease and require early chelation therapy to avoid the long term effects of iron overload. Knowledge on the incidence and nature of serious adverse drug events (e.g. neutropenia, agranulocytosis) that may lead to treatment termination is of importance in this lifelong therapy. Methods: The Hong Kong Clinical Data Analysis and Reporting System (CDARS) comprising data of more than 7 million patients was used to extract all thalassaemia patients who were receiving deferiprone below the age of 18 years. Adverse drug events (ADE) were identifi ed using a selected list of ICD-9 codes and laboratory data. All identifi ed events were assessed for causality by reviewing concomitant medications, diagnoses and laboratory data. Results: 93 patients were eligible for analysis; median age was 14 years (IQR 12-16). Median duration of deferiprone therapy was 18 months (IQR 7-32). 17 patients received monotherapy and 76 combination therapy with deferoxamine. Overall incidence rates for neutropenia, agranulocytosis, elevated liver enzymes and arthropathies were 9.7%, 5.4%, 8.6% and 3.2%; in patients with monotherapy 5.9%, 0%, 17.6% and 5.9% and with combination therapy 10.5%, 7.9%, 6.6% and 2.6%, respectively. 10 patients stopped deferiprone therapy during observation; 5, 3 and 2 patients due to agranulocytosis, arthropathies and elevated liver enzymes, respectively. 48.3% of these ADEs occurred during the fi rst 3 months of therapy. Conclusion: Combination therapy seems to be more prone for serious ADEs than monotherapy. This association must be further investigated in larger cohorts and clinical settings in paediatric patients.-
dc.languageengen_US
dc.publisherThe Pharmaceutical Society of Hong Kong. The Journal's web site is located at http://www.pshk.hk/main.php?id=62-
dc.relation.ispartofHong Kong Pharmaceutical Journalen_US
dc.subjectdeferiprone-
dc.subjectthalassaemia-
dc.subjectadverse drug event-
dc.subjectchildren-
dc.titleSerious adverse drug events during deferiprone therapy in paediatric thalassaemia Patientsen_US
dc.typeConference_Paperen_US
dc.identifier.emailSing, CW: wingsing@hku.hken_US
dc.identifier.emailWong, ICK: wongick@hku.hken_US
dc.identifier.authorityWong, ICK=rp01480en_US
dc.identifier.hkuros239884en_US
dc.identifier.volume20en_US
dc.identifier.issue3en_US
dc.identifier.spage143en_US
dc.identifier.epage143en_US
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats